Spyre Therapeutics files preliminary prospectus for common stock offeringOct 5FinancingSpyre Therapeutics, Inc.
Spyre Therapeutics registers Phase 2 SKYLIGHT trial of SPY072 in hidradenitis suppurativaAug 14Trial updateSPY002-072Spyre Therapeutics, Inc.